Work

Anti-CD20 monoclonal antibodies: historical and future perspectives

Year: 2009
Type: review
Abstract: Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2134677113
FWCI: 3.329
Cites: 122
Cited by: 254
Related to: 9